2003
DOI: 10.1509/jppm.22.2.181.17636
|View full text |Cite
|
Sign up to set email alerts
|

Consumers'Attention to the Brief Summary in Print Direct-to-Consumer Advertisements: Perceived Usefulness in Patient–Physician Discussions

Abstract: To what extent does direct-to-consumer prescription drug advertising communicate detailed technical information (e.g., relevant to risks, warnings, indications, contraindications, adverse effects)? This study examines whether consumers attend to the brief summary of risk information in product-specific print direct-to-consumer advertisements and whether they find it useful in discussing the risks of taking the drug with their physicians. The authors analyze data from a 1999 national survey of 1205 consumers. A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
18
0

Year Published

2004
2004
2021
2021

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 40 publications
(19 citation statements)
references
References 24 publications
1
18
0
Order By: Relevance
“…Although similar to those in other studies (e.g., Aikin, Swasy, & Braman, 2004;Menon et al, 2003;Slaughter, 2002), the high numbers in our study could be partly due to the fact that the figures are self-reports. Critics (e.g.…”
Section: Medical Professionals' Attitudes Toward Patients Asking For supporting
confidence: 91%
“…Although similar to those in other studies (e.g., Aikin, Swasy, & Braman, 2004;Menon et al, 2003;Slaughter, 2002), the high numbers in our study could be partly due to the fact that the figures are self-reports. Critics (e.g.…”
Section: Medical Professionals' Attitudes Toward Patients Asking For supporting
confidence: 91%
“…This information may be accessible through links from the home page and interior pages, in PDFs that report full prescribing information, or most commonly, on the bottom of the home page and selected interior pages, separated from the benefi t information requiring scrolling to read. 13 There is no specifi c research that reports how likely consumers are to read the bottom-of-page risk information, although one would expect the number to be quite low when one extrapolates from the relatively low number of individuals who read and pay attention to similar ' fi ne print ' or ' Brief Summary ' information on print DTC advertisements 14,15 and when one considers consumers ' preference that side effect information be placed higher rather then lower on a web page. 16 Although research has been conducted to determine better ways to present risk and side effect information outside of the Internet, 17,18 there is no empirical research that explores how manipulations of the form and placement of the side effect risk statement on a pharmaceutical web site affects the recall of specifi c side effects.…”
Section: Purpose Of the Researchmentioning
confidence: 99%
“…(4) effects of DTC drug advertising on non-consumer stakeholders and the health care system; (5) attitudes and behaviors of health care professionals toward DTC drug advertising; (6) DTC drug advertising public policy and regulatory issues; (7) message content of DTC drug advertising; and (8) content and format of DTC drug web sites (e.g., Allison-Ottey, Ruffin, and Allison 2002;Balazs, Yermolivich, and Zinkhan 2000;Bell, Wilkes, and Kravitz 2000;Calfee 2002;Coney 2002;Davis 2000;Deshpande et al 2003;FDA 1999;Findlay 2001;Graber and Weckmann 2002;Gonul, Carter, and Wind 2000;Hoek and Gendall 2002;Huh and Becker 2002;Kopp and Bang 2000;Macias and Lewis 2002;Menon et al 2003aMenon et al , 2003bWilkes, Bell, and Kravitz 2000;Zachary et al 2002).…”
Section: Health Marketing Quarterlymentioning
confidence: 99%